1. Home
  2. NX vs ABUS Comparison

NX vs ABUS Comparison

Compare NX & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quanex Building Products Corporation

NX

Quanex Building Products Corporation

HOLD

Current Price

$17.96

Market Cap

760.6M

Sector

Industrials

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.58

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NX
ABUS
Founded
1927
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
760.6M
839.5M
IPO Year
2008
2008

Fundamental Metrics

Financial Performance
Metric
NX
ABUS
Price
$17.96
$4.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$28.00
$5.00
AVG Volume (30 Days)
418.7K
1.9M
Earning Date
06-04-2026
05-14-2026
Dividend Yield
1.64%
N/A
EPS Growth
N/A
55.26
EPS
N/A
0.87
Revenue
$1,837,641,000.00
$14,083,000.00
Revenue This Year
$4.26
N/A
Revenue Next Year
$1.77
$239.71
P/E Ratio
N/A
$5.07
Revenue Growth
43.81
128.21
52 Week Low
$11.04
$3.04
52 Week High
$22.90
$5.10

Technical Indicators

Market Signals
Indicator
NX
ABUS
Relative Strength Index (RSI) 52.84 54.41
Support Level $16.90 $4.15
Resistance Level $18.07 $4.60
Average True Range (ATR) 0.89 0.17
MACD 0.20 0.01
Stochastic Oscillator 80.60 56.25

Price Performance

Historical Comparison
NX
ABUS

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its four operating segments are North American Fenestration being the key revenue driver, European Fenestration, North American Cabinet Components, and Tyman. Geographically, it derives a majority of revenue from the United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: